Pamela C L Ferreira
Overview
Explore the profile of Pamela C L Ferreira including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
359
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kolobaric A, Andreescu C, Gerlach A, Jasarevic E, Aizenstein H, Pascoal T, et al.
Alzheimers Dement
. 2025 Mar;
21(3):e14493.
PMID: 40042417
Introduction: Late-life cognitive impairment and depression frequently co-occur and share many symptoms. However, the specific neural and clinical factors contributing to both their common and distinct profiles in older adults...
2.
Son S, Lee D, Roh H, Ly M, Kolobaric A, Aizenstein H, et al.
Alzheimers Res Ther
. 2025 Feb;
17(1):52.
PMID: 40016766
Background: Recent studies have focused on improving our understanding of gut microbiome dysbiosis and its impact on cognitive function. However, the relationship between gut microbiome composition, accelerated brain atrophy, and...
3.
Leffa D, Povala G, Bellaver B, Ferrari-Souza J, Ferreira P, Lussier F, et al.
Alzheimers Dement
. 2025 Feb;
21(2):e70003.
PMID: 39998851
Introduction: Epidemiological studies indicate a link between attention-deficit/hyperactivity disorder (ADHD) and elevated risk of dementia. However, the impact of ADHD on cognition and Alzheimer's disease (AD) biomarkers in individuals with...
4.
Zeng X, Lafferty T, Sehrawat A, Chen Y, Ferreira P, Bellaver B, et al.
Mol Neurodegener
. 2024 Oct;
19(1):68.
PMID: 39385222
Background: Blood-based biomarkers are gaining grounds for the detection of Alzheimer's disease (AD) and related disorders (ADRDs). However, two key obstacles remain: the lack of methods for multi-analyte assessments and...
5.
Pascoal T, Aguzzoli C, Lussier F, Crivelli L, Suemoto C, Fortea J, et al.
EBioMedicine
. 2024 Oct;
108:105322.
PMID: 39366844
Biomarkers have been instrumental in population selection and disease monitoring in clinical trials of recently FDA-approved drugs targeting amyloid-β to slow the progression of Alzheimer's disease (AD). As new therapeutic...
6.
Macedo A, Therriault J, Tissot C, Aumont E, Servaes S, Rahmouni N, et al.
Neurobiol Aging
. 2024 Sep;
144:127-137.
PMID: 39326302
In Alzheimer's disease (AD), neuropsychiatric symptoms (NPS) correlate with tau deposition in the brain. Here, we investigated the association of PET-based Braak stages with NPS and assessed whether they predict...
7.
Povala G, De Bastiani M, Bellaver B, Ferreira P, Ferrari-Souza J, Lussier F, et al.
Alzheimers Dement
. 2024 Aug;
20(10):6709-6721.
PMID: 39140361
Introduction: Brain glucose hypometabolism, indexed by the fluorodeoxyglucose positron emission tomography ([F]FDG-PET) imaging, is a metabolic signature of Alzheimer's disease (AD). However, the underlying biological pathways involved in these metabolic...
8.
Zeng X, Lafferty T, Sehrawat A, Chen Y, Ferreira P, Bellaver B, et al.
medRxiv
. 2024 Jul;
PMID: 38947065
Background: Blood-based biomarkers are gaining grounds for Alzheimer's disease (AD) detection. However, two key obstacles need to be addressed: the lack of methods for multi-analyte assessments and the need for...
9.
Zhang Y, Ferreira P, Jacobsen E, Bellaver B, Pascoal T, Snitz B, et al.
Alzheimers Dement
. 2024 May;
20(6):4199-4211.
PMID: 38753951
Introduction: Plasma biomarkers of Alzheimer's disease and related dementias predict global cognitive performance and decline over time; it remains unclear how they associate with changes in different dementia syndromes affecting...
10.
Rosano C, Karikari T, Cvejkus R, Bellaver B, Ferreira P, Zmuda J, et al.
Alzheimers Dement (N Y)
. 2024 Apr;
10(2):e12460.
PMID: 38617114
Introduction: Alzheimer's disease (AD) is increasing in the Caribbean, especially for persons of African ancestry (PAA) and women. However, studies have mostly utilized surveys without AD biomarkers. Methods: In the...